Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Epigenetics modifications and Subclinical Atherosclerosis in Obstructive Sleep Apnea: The EPIOSA study

  • Marin, José M.
  • Artal, Jorge
  • Martin, Teresa
  • Carrizo, Santiago J.
  • Andrés, Marta
  • Martín Burriel, Inmaculada
  • Bolea, Rosa
  • Sanz, Arianne
  • Varona, Luis
  • Godino, Javier
  • Gallego, Begoña
  • Garcia-Erce, José A.
  • Villar, Isabel
  • Gil, Victoria
  • Forner, Marta
  • Cubero, José P.
  • Ros Mendoza, Luis H.
Background Obstructive sleep apnea (OSA) is associated with increased risk for cardiovascular morbidity and mortality. Epidemiological and animal models studies generate hypotheses for innovative strategies in OSA management by interferig intermediates mechanisms associated with cardiovascular complications. We have thus initiated the Epigenetics modification in Obstructive Sleep Apnea (EPIOSA) study (ClinicalTrials.gov identifier: NCT02131610). Methods/design EPIOSA is a prospective cohort study aiming to recruit 350 participants of caucasian ethnicity and free of other chronic or inflammatory diseases: 300 patients with prevalent OSA and 50 non-OSA subjects. All of them will be follow-up for at least 5 years. Recruitment and study visits are performed in single University-based sleep clinic using standard operating procedures. At baseline and at each one year follow-up examination, patients are subjected to a core phenotyping protocol. This includes a standardized questionnaire and physical examination to determine incident comorbidities and health resources utilization, with a primary focus on cardiovascular events. Confirmatory outcomes information is requested from patient records and the regional Department of Health Services. Every year, OSA status will be assessed by full sleep study and blood samples will be obtained for immediate standard biochemistry, hematology, inflammatory cytokines and cytometry analysis. For biobanking, aliquots of serum, plasma, urine, mRNA and DNA are also obtained. Bilateral carotid echography will be performed to assess subclinical atherosclerosis and atherosclerosis progression. OSA patients are treated according with national guidelines. Discussion EPIOSA will enable the prospective evaluation of inflammatory and epigenetics mechanism involved in cardiovascular complication of treated and non-treated patients with OSA compared with non OSA subjects.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Forkhead Box P3 Methylation and Expression in Men with Obstructive Sleep Apnea

  • Sanz-Rubio, David
  • Sanz, Arianne
  • Varona, Luis
  • Bolea, Rosa
  • Forner, Marta
  • Gil, Aana V.
  • Cubero, Pablo
  • Marin-Oto, Marta
  • Martin-Burriel, Inmaculada
  • Marin, José M.
BACKGROUND: Epigenetic changes in obstructive sleep apnea (OSA) have been proposed as a mechanism for end-organ vulnerability. In children with OSA, Forkhead Box P3 (FOXP3) DNA methylation were associated with inflammatory biomarkers; however, the methylation pattern and its effect in the expression of this gene have not been tested in adults with OSA. METHODS: Plasma samples from subjects without comorbid conditions other than OSA were analyzed (the Epigenetics Status and Subclinical Atherosclerosis in Obstructive Sleep Apnea (EPIOSA) Study: NCT02131610). In 16 patients with severe OSA (Apnea-Hypopnea Index-AHI- > 30 events/h) and seven matched controls (AHI < 5), methylation of FOXP3 gen was evaluated by PCR of the promoter and by pyrosequencing of the intron 1 Treg-specific demethylated region (TSDR). In another 74 patients with OSA (AHI > 10) and 31 controls, we quantified FOXP3 protein expression by ELISA and gene expression by quantitative real-time PCR. C-reactive protein (CRP) and plasma Treg cells were also evaluated. RESULTS: Neither the levels of the promoter nor the TSDR demethylated region were different between controls and patients with OSA, whether they were grouped by normal or high CRP. FOXP3 protein and mRNA expression did not differ between groups. CONCLUSIONS: FOXP3 methylation or its expression is not altered in adults with OSA, whatever their inflammatory status.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Otros (Other)

Sleep apnoea: From numbers to the people

  • Marín, J. M.
Obstructive sleep apnoea (OSA) is defined as the presence of more than five events of complete obstruction (apnoea) or partial obstruction (hypopnoea) of the pharynx [apnoea–hypopnoea index (AHI) >5] per hour of sleep. Amongst adults, more than 24% of men and 9% of women suffer from OSA each night 1. When a patient with OSA presents daytime sleepiness that affects work or social activity, OSA syndrome is diagnosed. Almost all patients with OSA snore and experience unrefreshed sleep but tend not to consult their general practitioner (GP) regarding this symptomatology. In most cases, patients visit their doctor at the request of their partner who has observed cessation of breathing during sleep or inappropriate DS. Overall, OSA is underdiagnosed and therefore undertreated. Despite this, it is currently a very common cause of GP consultation. The high prevalence of OSA in the industrialized world is related to the increasing prevalence of its main risk factor: obesity. Excessive fat deposit in the pharynx reduces the diameter of the upper airway and favours its collapse during sleep, when the tone of the intrinsic muscles of the pharynx is reduced compared to wake time.